The laboratories of GSK in Wavre, the Pharmaceutical giant (30 vaccines against different diseases, two million units distributed worldwide every day), have produced the first doses of adjuvant for the future vaccine against the coronavirus. This vaccine is developed in partnership with another heavyweight in the sector, the Sanofi group.
Barré mobilized its teams to manufacture and install part of the production chain for this adjuvant on time.
Adjuvant is a substance that increases the effectiveness of the antigen which is used to cause an immune response in our body. The adjuvant technology itself was discovered by the Belgian GSK laboratories. The company employs 9,000 people in our country, mainly at the Rixensart and Wavre sites in Walloon Brabant.
GSK and Sanofi have already signed agreements with several national or supranational bodies for a total of more than 732 million doses of vaccine, including 300 million doses for the European Union.
Galerie médias
